|
1."International Ciabetes Federation. IDF Diabetes Atlas 10th edition 2021. Western Pacific [Internet] 2021 11/08/2021 [cited 2023 12/20]; 10:[Available from: https://diabetesatlas.org/data/en/region/8/wp.html.
2.Sun, H., et al., IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract, 2022. 183: p. 109119.
3.潘文涵, 國民營養健康狀況變遷調查 (102-105 年), 衛生福利部國民健康署, Editor. 2019. p. 72.
4.潘文涵, 國民營養健康狀況變遷調查(106－109年), 衛生福利部國民健康署, Editor. 2022. p. 82.
5.衛福部國民健康署, 2007年台灣地區高血壓、高血糖、高血脂之追蹤調查研究, 衛福部國民健康署, Editor. 2008, 衛福部國民健康署: 衛福部國民健康署.
6.社團法人中華民國糖尿病衛教學會, 臺灣糖尿病年鑑. 2019第2型糖尿病. 2019, 臺灣.
7.社團法人中華民國糖尿病衛教學會, 臺灣糖尿病年鑑. 2020第1型糖尿病. 2020, 臺灣.
8.”International Diabetes Federation, Diabetes Complications. Vol. 2024. Brussels, Belgium.
9.衛生福利部統計處. 111年死因統計結果. [Internet] 112 2023/08/31 [cited 2024 03/15]; Available from: https://dep.mohw.gov.tw/DOS/lp-5069-113-xCat-y111.html.
10.Lo, W.-C., et al., Adult mortality of diseases and injuries attributable to selected metabolic, lifestyle, environmental, and infectious risk factors in Taiwan: a comparative risk assessment. Population Health Metrics, 2017. 15(1): p. 17.
11.Ojo, O.A., et al., Diabetes mellitus: From molecular mechanism to pathophysiology and pharmacology. Medicine in Novel Technology and Devices, 2023. 19: p. 100247.
12."DiABETES UK. diabetes and heart disease. [Internet] 2022 08/24 [cited 2024 04/09]; Available from: https://www.diabetes.org.uk/guide-to-diabetes/complications/cardiovascular_disease.
13.Xie, J., et al., Global burden of type 2 diabetes in adolescents and young adults, 1990-2019: systematic analysis of the Global Burden of Disease Study 2019. Bmj, 2022. 379: p. e072385.
14.Wagenknecht, L.E., et al., Trends in incidence of youth-onset type 1 and type 2 diabetes in the USA, 2002-18: results from the population-based SEARCH for Diabetes in Youth study. Lancet Diabetes Endocrinol, 2023. 11(4): p. 242-250.
15.Liu, L.L., et al., Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. Pediatr Diabetes, 2010. 11(1): p. 4-11.
16.Koye, D.N., et al., Temporal Trend in Young-Onset Type 2 Diabetes-Macrovascular and Mortality Risk: Study of U.K. Primary Care Electronic Medical Records. Diabetes Care, 2020. 43(9): p. 2208-2216.
17.Chuang, L.M., et al., Comparisons of the outcomes on control, type of management and complications status in early onset and late onset type 2 diabetes in Asia. Diabetes Res Clin Pract, 2006. 71(2): p. 146-55.
18.Yeung, R.O., et al., Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study of a prospective cohort. Lancet Diabetes Endocrinol, 2014. 2(12): p. 935-43.
19.Wei, J.N., et al., National surveillance for type 2 diabetes mellitus in Taiwanese children. Jama, 2003. 290(10): p. 1345-50.
20.Hillier, T.A. and K.L. Pedula, Complications in young adults with early-onset type 2 diabetes: losing the relative protection of youth. Diabetes Care, 2003. 26(11): p. 2999-3005.
21.Zeitler, P., et al., Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes, 2007. 8(2): p. 74-87.
22.Song, S.H. and C.A. Hardisty, Early onset type 2 diabetes mellitus: a harbinger for complications in later years—clinical observation from a secondary care cohort. QJM: An International Journal of Medicine, 2009. 102(11): p. 799-806.
23.Chan, J.C., et al., Premature mortality and comorbidities in young-onset diabetes: a 7-year prospective analysis. Am J Med, 2014. 127(7): p. 616-24.
24.Huo, X., et al., Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study. Lancet Diabetes Endocrinol, 2016. 4(2): p. 115-24.
25.Zou, X., et al., The characteristics of newly diagnosed adult early-onset diabetes: a population-based cross-sectional study. Scientific Reports, 2017. 7(1): p. 46534.
26.Hu, C., et al., Association Between Age at Diagnosis of Type 2 Diabetes and Cardiovascular Diseases: A Nationwide, Population-Based, Cohort Study. Front Endocrinol (Lausanne), 2021. 12: p. 717069.
27.Constantino, M.I., et al., Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care, 2013. 36(12): p. 3863-9.
28.中華民國糖尿病學會. 糖化血色素(HbA1c)值. [Internet] 2011 2011/05/31 [cited 2024 05/19]; Available from: http://www.diabetes.org.tw/wddt_heduc01.jsp?P_TNO=EDUC990010005&P_HCTG=A.
29.Committee, A.D.A.P.P., 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2024. Diabetes Care, 2023. 47(Supplement_1): p. S111-S125.
30."The Diabetes Association of the Republic of China (Taiwan) (2022), DAROC Clinical Practice Guidelines for Type 1 Diabetes Care- 2022. 2022, Taipei, Taiwan: The Diabetes Association of the Republic of China (Taiwan).
31.Diabetes Association of the R.O.C., DAROC Clinical Practice Guidelines for Type 2 Diabetes Care- 2022. 2022, Taiwan.
32.Riddle, M.C., The Treat-to-Target Trial and related studies. Endocr Pract, 2006. 12 Suppl 1: p. 71-9.
33.Wangnoo, S.K., et al., Treat-to-target trials in diabetes. Indian J Endocrinol Metab, 2014. 18(2): p. 166-74.
34.Eeg-Olofsson, K., et al., New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). J Intern Med, 2010. 268(5): p. 471-82.
35.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998. 352(9131): p. 837-53.
36.Holman, R.R., et al., 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008. 359(15): p. 1577-89.
37.Stratton, I.M., et al., Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj, 2000. 321(7258): p. 405-12.
38.Patel, A., et al., Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med, 2008. 358(24): p. 2560-72.
39.Gerstein, H.C., et al., Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008. 358(24): p. 2545-59.
40.Nathan, D.M., et al., Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 2005. 353(25): p. 2643-53.
41.Bebu, I., et al., Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care, 2020. 43(4): p. 867-874.
42.Zeitler, P., et al., A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med, 2012. 366(24): p. 2247-56.
43.Bjornstad, P., et al., Long-Term Complications in Youth-Onset Type 2 Diabetes. N Engl J Med, 2021. 385(5): p. 416-426.
44.Nanayakkara, N., et al., Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses. Diabetologia, 2021. 64(2): p. 275-287.
45.Si, D., et al., Comparison of diabetes management in five countries for general and indigenous populations: an internet-based review. BMC Health Services Research, 2010. 10(1): p. 169.
46.Lai, M.-S. and S.-T. Chiou, Concept and Content of Diabetes Shared Care. Formosan Journal of Medicine, 2002. 6(4): p. 560-568.
47.Chen, Y.-Y. and Y.-C. Tung, Association between value-based payments and quality of diabetes care. Taiwan Journal of Public Health, 2023. 42(6): p. 689-699.
48.Lee, I.T., et al., Pay-for-performance for shared care of diabetes in Taiwan. J Formos Med Assoc, 2019. 118 Suppl 2: p. S122-s129.
49.Tan, E.C., et al., Is a diabetes pay-for-performance program cost-effective under the National Health Insurance in Taiwan? Qual Life Res, 2014. 23(2): p. 687-96.
50.Hsieh, H.M., et al., Cost-effectiveness of diabetes pay-for-performance incentive designs. Med Care, 2015. 53(2): p. 106-15.
51.Yang, Y.H., et al., Effectiveness of diabetes shared care program on metabolic indicators of people with type 2 diabetes: A systematic review and meta-analysis. Prim Care Diabetes, 2024. 18(3): p. 257-267.
52.Pan, C.C., et al., Patients with diabetes in pay-for-performance programs have better physician continuity of care and survival. Am J Manag Care, 2017. 23(2): p. e57-e66.
53.Chen, C.C. and S.H. Cheng, Does pay-for-performance benefit patients with multiple chronic conditions? Evidence from a universal coverage health care system. Health Policy Plan, 2016. 31(1): p. 83-90.
54.Lu, C.W., et al., A nationwide cohort investigation on pay-for-performance and major adverse limb events in patients with diabetes. Prev Med, 2021. 153: p. 106787.
55.Li, P.I. and H.R. Guo, Long-term quality-of-care score for predicting the occurrence of acute myocardial infarction in patients with type 2 diabetes mellitus. World J Diabetes, 2023. 14(7): p. 1091-1102.
56.Lipscombe, L.L., et al., Identifying diabetes cases from administrative data: a population-based validation study. BMC Health Serv Res, 2018. 18(1): p. 316.
57.KU, F.-P., et al., Variations in case definition algorithms in diabetes-related studies using Taiwan National Health Insurance claims data. Taiwan Journal of Public Health, 2021. 40(6): p. 725-733.
58.Chen, H.-F., et al., Incidence of idiopathic cardiomyopathy in patients with type 2 diabetes in Taiwan: age, sex, and urbanization status-stratified analysis. Cardiovascular Diabetology, 2020. 19(1): p. 177.
59.財團法人腎臟病防治基金會. 腎絲球過濾率計算. [Internet] 2020 [cited 2024 06/14]; 使用MDRD公式]. Available from: https://www.tckdf.org.tw/Main/GFR02.
60.國民健康署使用. 腎絲球過濾率(eGFR)及低密度脂蛋白膽固醇(LDL)計算公式. [Internet] 2015 2018/01/22 [cited 2024 06/14]; Available from: https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=1115&pid=6472.
61.Schwartz, G.J., et al., New equations to estimate GFR in children with CKD. J Am Soc Nephrol, 2009. 20(3): p. 629-37.
62.Hsieh, H.M., et al., The association between participation in a pay-for-performance program and macrovascular complications in patients with type 2 diabetes in Taiwan: A nationwide population-based cohort study. Prev Med, 2016. 85: p. 53-59.
63.Bacha, F., et al., Determinants of glycemic control in youth with type 2 diabetes at randomization in the TODAY study. Pediatr Diabetes, 2012. 13(5): p. 376-83.
64.Tromp, J., et al., Age dependent associations of risk factors with heart failure: pooled population based cohort study. Bmj, 2021. 372: p. n461.
65.Huo, L., et al., Impact of age at diagnosis and duration of type 2 diabetes on mortality in Australia 1997–2011. Diabetologia, 2018. 61(5): p. 1055-1063.
66.Chen, Y.C., et al., Impact of pay-for-performance on mortality in diabetes patients in Taiwan: A population-based study. Medicine (Baltimore), 2016. 95(27): p. e4197.
67.Chou, C.W., et al., Pay-for-performance programmes reduce stroke risks in patients with type 2 diabetes: a national cohort study. BMJ Open, 2019. 9(10): p. e026626.
68.Sarwar, N., et al., Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet, 2010. 375(9733): p. 2215-22.
69.Group, T.S., Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. Diabetes care, 2013. 36(6): p. 1749-1757.
70.Postintervention Effects of Varying Treatment Arms on Glycemic Failure and β-Cell Function in the TODAY Trial. Diabetes Care, 2021. 44(1): p. 75-80.
71.衛生福利部國民健康署. 國人吸菸行為調查結果. [Internet] 2023 2024/06/25 [cited 2024 07/04]; Available from: https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=1718&pid=9913.
72.Gao, M., et al., The Impact of Different Antihypertensive Drugs on Cardiovascular Risk in Isolated Systolic Hypertension with Type 2 Diabetes Patients. J Clin Med, 2022. 11(21).
73.Colhoun, H.M., et al., Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004. 364(9435): p. 685-96.
74.Kannel, W.B., et al., Role of blood pressure in the development of congestive heart failure. The Framingham study. N Engl J Med, 1972. 287(16): p. 781-7.
75.Levy, D., et al., The progression from hypertension to congestive heart failure. Jama, 1996. 275(20): p. 1557-62
|